UK estimates of 'drug-related deaths' (DRDs) include mortalities of drug abusers and non-drug abusers. So these figures may not be the best way of monitoring the performance of Drug and Alcohol Action Teams, a study published in the online open access journal Substance Abuse Treatment, Prevention and Policy suggests.
DRDs are currently used to help evaluate the success of Drug and Alcohol Action Teams in England and Wales, but the term's exact meaning varies according to European and national definitions. This means it is hard to know what sorts of deaths are included, the demographic profile of those who died, and whether or not individuals were tapped in to services designed to assist drug abusers.
Dr. Caryl Beynon from Liverpool John Moores University and colleagues studied details of 70 DRDs that occurred over an 18 month period in Liverpool - the UK city with the highest recorded number of DRDs in 2004.
They found their sample included drug abusers and non-drug abusers. The latter tended to be older, had no recent contact with drug-related agencies, and had different post-mortem drug profiles - they were more likely to have died from the toxic effects of anti-depressants, anti-psychotics and analgesics than from taking 'problematic' drugs (e.g. heroin, crack cocaine/cocaine). Generally the figures also excluded deaths related to drug misuse, such as those caused by bacterial and viral infections via sharing drug injecting equipment or contaminated drugs. DRD figures don't capture the true burden of drug-related mortality as the figures include a wide range of disparate deaths and exclude others which are clearly related to the abuse of drugs, the authors conclude.
When is a drug-related death not a drug-related death" Implications for current drug-related death policies in the UK and Europe
Caryl M Beynon, Mark A Bellis, Elaine Church and Sue Neely
Substance Abuse Treatment, Prevention, and Policy (in press)
During embargo, article available at: http://www.substanceabusepolicy.com/imedia/1018513459142556_article.pdf?random=289466
After the embargo, article available from the journal website at: http://www.substanceabusepolicy.com/
Article citation and URL available on request at email@example.com on the day of publication
For author contact details please contact Michela Morleo (Press Office, Liverpool John Moores University) by phone 0151 2314535 or email M.J.Morleo@ljmu.ac.uk
BioMed Central (http://www.biomedcentral.com) is an independent online publishing house committed to providing open access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science.
BioMed Central currently publishes over 160 journals across biology and medicine. In addition to open-access original research, BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.